Mesothelioma Growth Could be Linked to Density of Cancer Cells – MesotheliomaHelp.org (blog)

As MesotheliomaHelp has reported time and again, the spread of cancer cells, or metastasis, is the biggest challenge for researchers when searching for effective treatments. It is this migration of the cancer cells, according to the National Cancer Society, that is the cause of 90 percent of all cancer deaths. Stopping this spread is critical for improving survival in mesothelioma patients. Now, researchers report they have found the reason cancer cells split off from the primary site, and more importantly, they may also know how to stop the process.

In a May 26 press release from Johns Hopkins, lead researcher Hasini Jayatilaka, a postdoctoral fellow at Johns Hopkins Physical Sciences-Oncology Center, found that it is not the overall size of a tumor that leads to metastasis, rather how tightly those cells are jammed together that has them break away. Jayatilaka likened the process to waiting for a table in an overcrowded restaurant but then deciding to go elsewhere or moving to the suburbs from the crowded city.

Cancer cells metastasize because they can reproduce quickly and they can get into the bloodstream where they then spread to other organs. When looking deeper into those processes, the team found that when the tumors became more crowded the cells secreted proteins that encouraged migration. The proteins, Interleukin 6 (IL-6) and Interleukin 8 (IL-8), sent signals basically telling the cancer cells to leave the primary tumor site.

We found that it was not the overall size of a primary tumor that caused cancer cells to spread, but how tightly those cells are jammed together when they break away from the tumor, said Jayatilaka. At a fundamental level, we found that cell density is very important in triggering metastasis.

When the researchers used two existing drugs at the tumor site, one approved for treating arthritis and the other being tested for breast cancer treatment, the receptors were blocked from receiving those signals, effectively halting the metastasis. Although the growth at the primary tumor site did not stop, the spread of the cancer cells was limited. This helped confirm that by blocking the signaling pathway, they could slow metastasis.

Dr. Denis Wirtz, Johns Hopkins

In our eight-week experiment, when we used these two drugs together, the growth of the primary tumor itself was not stopped, but the spread of the cancer cells was significantly decreased, Jayatilaka said. We discovered a new signaling pathway that, when blocked, could potentially curb cancers ability to metastasize.

Once mesothelioma cells spread to distant regions of the body, the cancer, caused by past asbestos exposure, becomes virtually impossible to eradicate. Getting a handle on the spread of cancer is critical for increasing survival.

The pharmaceutical companies view metastasis as a by-product of tumor growth, said Denis Wirtz, Johns Hopkins Universitys vice provost for research and director of its Physical Sciences-Oncology Center, and one of the studys senior authors. Our study looked more closely at the steps that actually initiate metastasis. By doing this, we were able to develop a unique therapeutic that directly targets metastasis, not the growth of the primary tumor.

This drug cocktail was tested on mice in the lab, but has not yet been tested on humans. Wirtz said the feedback they have gotten from other researchers has been positive and others see real potential for this approach.

Mesothelioma, an asbestos-caused cancer is diagnosed in close to 3,000 Americans each year. There is no cure for the asbestos-caused cancer.

See the full study in the May 26 online issue of Nature Communications.

Read more:

Mesothelioma Growth Could be Linked to Density of Cancer Cells - MesotheliomaHelp.org (blog)

Mesothelioma Compensation Center Now Urges a Chemical Plant Worker with Mesothelioma to Call About Why They … – PR Newswire (press release)

NEW YORK, June 28, 2017 /PRNewswire/ --The Mesothelioma Compensation Center says, "Because a chemical plant worker with mesothelioma could get financial compensation that might exceed one million dollars, we are urging a person like this or their family to call us anytime at 800-714-0303 to ensure they are talking directly to the nation's most skilled and capable mesothelioma attorneys.

"Please do not make the mistake of hiring a local car accident attorney for something as complicated as a mesothelioma compensation claim involving a chemical plant. Because these types of compensation claims can be quite complicated, you will only want a full-time mesothelioma attorney who has experiences with financial claims involving asbestos exposure at a chemical plant." http://MesotheliomaCompensationCenter.Com

States with the most chemical plants/U.S. Bureau of Labor Statistics:

For more information about chemical plants in the United States please refer to the U.S. Bureau of Labor Statistics website: https://www.bls.gov/oes/current/oes518091.htm

The Mesothelioma Compensation Center is also urging people with mesothelioma to ignore Internet ads that suggest 'no lawsuit needed', and/or similar nonsense. The mesothelioma attorneys they suggest typically do not advertise because they don't have to. Frequently, Internet ads about mesothelioma or mesothelioma attorneys are sponsored by law firms that market to victims of mesothelioma with the goal to sell the case to another firm to do the actual work.

As the group would like to discuss anytime at 800-714-0303, "You need to be dealing directly with the nation's top mesothelioma attorneys if you want to get the best possible financial compensation for this rare asbestos exposure cancer; you do not need a middleman law firm to assist." http://MesotheliomaCompensationCenter.Com

The Mesothelioma Compensation Center specializes in assisting US Navy Veterans, power plant workers, shipyard workers,oil refinery workers, public utility workers, hydro-electric workers, chemical plant workers, nuclear power plant workers, manufacturing workers, oil and gas field production workers, plumbers, electricians, millwrights, pipefitters and welders who have been diagnosed with mesothelioma. In most instances, these people were exposed to asbestos during the 1950's, 1960's, 1970's, or 1980's.

US Navy Veterans accountfor-a significant portion-of all diagnosed victims of mesothelioma each year. The average age for a diagnosed victim of mesothelioma is about 70 years old. Each year between 2500, and 3000 US citizens will be diagnosed with mesothelioma. Mesothelioma is attributable to exposure to asbestos.

According to the CDC the states indicated with the highest incidence of mesotheliomainclude Maine, Massachusetts, Connecticut, Maryland,New Jersey, Pennsylvania, Ohio, West Virginia, Virginia,Michigan, Illinois, Minnesota, Louisiana, Washington, and Oregon. However, a chemical plant worker with mesothelioma could live in any state including California, New York, Florida,Texas,Illinois, Ohio, Missouri, North Carolina,Kentucky, Tennessee, Georgia, Mississippi,Alabama, Kansas, Nebraska, New Mexico, Utah, Arizona, Nevada,Idaho, or Alaska.

The Mesothelioma Compensation Center says, "If you call us at 800-714-0303, we will see to it that you have on the spot access to the nation's most skilled, and experienced mesothelioma attorneys, becausethese incredibly skilled legal experts consistently get the best financial compensation results for their clients on a nationwide basis." http://MesotheliomaCompensationCenter.Com

For more information about mesothelioma please refer to the National Institutes of Health's web site related to this rare form of cancer: http://www.nlm.nih.gov/medlineplus/mesothelioma.html

Media contact: Michael Thomas 163150@email4pr.com 800-714-0303

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mesothelioma-compensation-center-now-urges-a-chemical-plant-worker-with-mesothelioma-to-call-about-why-they-need-very-skilled-attorneys-to-assist-them-with-their-compensation-claim-300480991.html

SOURCE Mesothelioma Compensation Center

http://MesotheliomaCompensationCenter.Com

More here:

Mesothelioma Compensation Center Now Urges a Chemical Plant Worker with Mesothelioma to Call About Why They ... - PR Newswire (press release)

Navy Veteran’s Mesothelioma Case Allowed to Proceed, Despite Asbestos Companies’ Objections – Mesothelioma.net Blog (blog)

The family of a deceasedveteranwho served four years in the Navy and who died of malignant mesotheliomawill be able to proceed with their mesothelioma lawsuit against multiple asbestos companies, despite those companies trying desperately to argue against his claim. The companies had attempted to bar testimony hed given as hearsay and his identification of their products onboard his Navy ship as inappropriately documented, but the Superior Court of Rhode Island refused to provide them with the summary judgment that they sought.

Despite the fact that it has been well established that asbestos causes malignant mesothelioma, asbestos companies continue to fight tooth and nail against having to provide compensation to those who their products harmed. The case of Paul F. McCarthy is a telling example of this. Mr. McCarthy served in the Navy from June of 1951 through June of 1955. After his period of basic training he was assigned to the U.S.S. Glennon. While onboard the Glennon he served as a member of the deck force, then moved on to the position of quartermaster. His responsibilities included a number of assignments that exposed him to asbestos. In May of 2013 he was diagnosed with malignant mesothelioma and he provided a sworn statement to his attorney, with a court reporter present, on July 1, 2013 regarding his time onboard the ship, testifying to the fact that when the ships guns fired asbestos dust would fall, and as to what products he worked with. His mesothelioma lawsuit was filed on July 17th and he died on November 13th of that year.

The asbestos companies named in the lawsuit asked that the case be dismissed, arguing that his testimony was hearsay and that the accuracy of his identification of their products as the cause of his illness was insufficient for the court to proceed. On consideration of both arguments, the court disagreed, indicating that his testimony was provided in good faith and falling under the category of a Statement Under Belief of Impending Death, and that it was up to a jury to determine whether there was sufficient evidence of an asbestos-contaminated products role in his death. His surviving family will be able to continue with their claim, seeking compensation for his medical expenses and the losses that they suffered as a result of his death.

Being diagnosed with mesothelioma is an emotional and financial challenge. Understanding your rights and the resources available to you is essential to being able to get through the ordeal, and thats what the Patient Advocates at Mesothelioma.net can provide. Contact us today at 1-800-692-8608to learn more about how we can help.

Terri Oppenheimer is an independent writer, editor, and proofreader. She graduated from the College of William and Mary with a degree in English. Her dreams of a writing career were diverted by a need to pay her bills. She spent a few years providing the copy for a major retailer, then landed a lucrative career in advertising sales. With college bills for all three of her kids paid, she left corporate America for a return to her original goal of writing. She specializes in providing content for websites and finds tremendous enjoyment in the things she learns while doing her research. Her specific areas of interest include health and fitness, medical research, and the law.

Originally posted here:

Navy Veteran's Mesothelioma Case Allowed to Proceed, Despite Asbestos Companies' Objections - Mesothelioma.net Blog (blog)

Seattle Cancer Center Opens Latest Mesothelioma Clinical Trial – Asbestos.com

The Seattle Cancer Care Alliance has opened a phase II clinical trial involving durvalumab, the promising immunotherapy drug, in combination with chemotherapy for the first-line treatment of unresectable pleural mesothelioma.

The U.S. Food and Drug Administration (FDA) already granted accelerated approval to durvalumab in May for the treatment of bladder cancer. Researchers have also lauded the drug for its effectiveness in earlier lung cancer clinical trials.

We have every reason to believe it will be effective with mesothelioma, too, Dr. Bernardo Goulart, chief trial investigator and medical oncologist at the Seattle Cancer Care Alliance (SCCA) told Asbestos.com. There is great logic behind it. We think this trial offers real hope for these patients.

Durvalumab activates a patients immune system to exert a cytotoxic response against tumor cells that overexpress the PD-L1 protein, which is common in several cancers, including mesothelioma.

The PD-L1 protein typically allows tumor cells to avoid a patients immune system.

This is the first time researchers test durvalumab in combination with chemotherapy in a first-line setting for mesothelioma. To qualify for this multicenter trial, patients must not have begun any other type of treatment.

Immunotherapy is going to play a big role in improving outcomes for these patients, Goulart said. After decades of no reasonable options, the future is looking brighter. Immunotherapy is one reason for that. This trial will help us help more patients.

U.S. News and World Report ranked SCCA among the top 10 Best Hospitals for Cancer Care in America in 2016. The hospital has made the list for more than a decade.

SCCA, which includes the University of Washington Medical Center and the Fred Hutchinson Cancer Research Center, has accelerated its role as a mesothelioma specialty center in recent years.

We want people to know that we are a center dedicated to treatment of this disease, Goulart said. We can offer options that other places just cant. I think we see this disease in a different way than others do.

The trial also is being held at other highly regarded cancer centers such as:

The primary purpose of the study is to determine whether adding durvalumab to pemetrexed and cisplatin or carboplatin will increase survival time. It also will measure response rate and progression-free survival.

Patients will be given the drug combination for six, three-week cycles. After completion, patients with stable or responding disease will then receive durvalumab alone every three weeks as maintenance until there is disease progression.

Other researchers are conducting two smaller studies on durvalumab to test its effectiveness with mesothelioma.

The Lung Institute at Baylor College of Medicine in Houston, which is headed by well-known mesothelioma specialist Dr. David Sugarbaker, is studying its effectiveness with surgery as a single agent and alongside tremelimumab, another type of immunotherapy drug.

The Dana Farber Cancer Institute in Boston is evaluating the effectiveness of the durvalumab/tremelimumab combination in second-line treatment for those with unresectable disease.

The multinational biopharmaceutical company AstraZenaca, based in Cambridge, England, markets durvalumab under the brand name Imfinzi.

The study of durvalumab, and other more well-known immunotherapy drugs such as pembrolizumab (Keytruda) and nivolumab (Opdivo), is critical to advancing treatment for mesothelioma. The FDA still has not approved any second-line treatment for the disease.

The first-line standard of care for mesothelioma remains a combination of surgery, chemotherapy and radiation, which hasnt changed in more than a decade.

An estimated 3,000 people annually in the United States are diagnosed with mesothelioma, which is typically traced to long-before occupational exposure to asbestos.

Some patients who come to us with mesothelioma already have been told by their doctor they have only 6-12 months to live, and there is nothing they can do, Goulart said. But there are options here. This trial is just one of those options.

See the original post here:

Seattle Cancer Center Opens Latest Mesothelioma Clinical Trial - Asbestos.com

New Mesothelioma Study Highlights Benefits of Compound in Cruciferous Vegetables, According to Surviving … – Benzinga

Korean researchers say sulforaphane may enhance the cancer-killing power of cisplatin.

Raleigh, NC (PRWEB) June 29, 2017

Scientists say the organosulfur compound sulforaphane found in vegetables like broccoli, cabbage, and cauliflower may have a role to play in the chemotherapeutic treatment of mesothelioma. Surviving Mesothelioma has the full story on the new research. Click here to read it now.

When doctors at Soonchunhyang University combined sulforaphane and cisplatin and applied the mixture to human pleural mesothelioma cells in the lab, the results were encouraging.

"Combination treatment with the two compounds exhibited synergistic growthinhibiting and apoptosispromoting [cell death] activities, as demonstrated by a series of proapoptotic events," write researchers Yoon-Jin and Sang-Han Lee.

Their study, published in the journal Molecular Medicine Reports, found that the combination of sulforaphane and cisplatin was even more effective when another compound was used first to inhibit the cell component recycling process known as autophagy.

"This is a complex study with a simple message: Sulforaphane clearly has anti-cancer properties," says Alex Strauss, Managing Editor for Surviving Mesothelioma. "The challenge going forward will be to determine how best to use these properties to expand treatment options for the 2,500 Americans diagnosed with malignant mesothelioma each year."

There is more information about the Korean study on sulforaphane in Compound in Broccoli May Enhance Mesothelioma Treatment with Cisplatin, now available on the Surviving Mesothelioma website.

Lee, YJ and Lee, SH, "Pro-oxidant activity of sulforaphane and cisplatin potentiates apoptosis and simultaneously promotes autophagy in malignant mesothelioma cells", June 15, 2017, Molecular Medicine Reports, Epub ahead of print, https://www.spandidos-publications.com/10.3892/mmr.2017.6789

For more than a decade, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

For the original version on PRWeb visit: http://www.prweb.com/releases/2017/06/prweb14470048.htm

More here:

New Mesothelioma Study Highlights Benefits of Compound in Cruciferous Vegetables, According to Surviving ... - Benzinga

Mesothelioma Nurse Remembers Doug Larkin, Co-Founder of Asbestos Disease Awareness Organization – MesotheliomaHelp.org (blog)

There are few people that are passionate leaders for change. These leaders see something that needs to be changed or a situation that needs to be exposed and they take their zeal and passion and make it happen. The mesothelioma community lost one of those leaders this month: Doug Larkin.

In 2004, he and Linda Reinstein co-founded the Asbestos Disease Awareness Organization. Based on a personal loss of his father-in-law, he took his grief and turned it into positive advocacy. He hoped to prevent asbestos exposure and to someday eliminate all asbestos-caused diseases. ADAO was personal to Doug.

I had the pleasure of meeting Doug at an ADAO conference a couple of years ago. We were impressed with his passion and his eloquence. He was a force, and I remember being impressed with his dedication to banning asbestos. He has made a difference, and left this world a better place for being in it.

Unparalleled champion for truth, justice, and an asbestos ban; Bold brilliant and courageous are the words being used to describe Doug on the ADAO web site.

In addition to fighting to ban asbestos so that the dying from asbestos related diseases would stop, Doug had a personal battle with ALS, Amyotrophic Lateral Sclerosis. Rest in peace, job well done.

Photo Credit: ADAO

Read the original:

Mesothelioma Nurse Remembers Doug Larkin, Co-Founder of Asbestos Disease Awareness Organization - MesotheliomaHelp.org (blog)

Companies Join Forces to Combat Mesothelioma – MesotheliomaHelp.org (blog)

In November, MesotheliomaHelp reported on the encouraging results with the experimental cancer drug known as CRS-207 in its ongoing Phase 1b trial. Now Aduro Biotech, the maker of CRS-207, is joining forces with Merck, the pharmaceutical company that markets the immunotherapy drug Keytruda (pembrolizumab), to determine whether the combination of the two medications is effective in the treatment of malignant pleural mesothelioma.

Pleural mesothelioma is the signature cancer of asbestos that attacks the linings of the lungs. Although recent breakthroughs in treatment have improved the life expectancy for some patients, the prognosis for patients is poor with survival often less than 18 months. New, effective treatments are critical to bring hope to the mesothelioma community.

According to a May 17 press release from Aduro Biotech announcing the collaboration, based on the results of the companys Phase 1 mesothelioma trial, and those of other studies that have shown positive results with the combination therapy, the companies are moving forward with the Phase 2 trial.

Data from our ongoing Phase 1 clinical trial of CRS-207 with standard chemotherapy as frontline treatment for malignant pleural mesothelioma have been very encouraging, said Natalie Sacks, M.D., chief medical officer at Aduro. we look forward to initiating a Phase 2 trial to evaluate the CRS-207/pembrolizumab combination in patients with malignant pleural mesothelioma who have failed prior treatment.

The Phase 2 trial is currently recruiting patients with a goal to enroll 35 mesothelioma patients whose cancer has continued to progress despite undergoing one or two prior anti-cancer therapies. The trial, that has an estimated completion date of March 2019, is an extension of a collaboration between the two companies testing the same combination of drugs in gastric cancers.

According to Aduro Biotech, CRS-207 is a Listeria-based vaccine that has been engineered to stimulate an immune response to mesothelin, which is over-expressed in many cancers, including mesothelioma. According to one study, more than half of the mesothelioma patients at diagnosis had significantly elevated levels of mesothelin in their blood.

Keytruda, an immunotherapy drug from Merck that awakens the immune system to effectively fight off cancer cells, has been approved in the U.S. for use in melanoma and lung cancer patients after a prior round of chemotherapy failed to stop progression of the disease. Keytruda works by targeting the cellular pathway known as PD-1/PD-L1 (proteins found on the bodys immune cells and some cancer cells). Most recently, the U.S. Food and Drug Administration has granted accelerated approval to Keytruda as a treatment based solely on the genetic mutations of a cancer and not on the type of cancer.

The CRS-207/pembrolizumab mesothelioma trial will take place at various centers across the U.S. Currently, the Moffitt Cancer Center in Tampa, FL and University of Chicago Medical Center are recruiting patients. Mesothelioma patients should talk to their oncologist to determine if this trial might be right for them.

To find out more about the collaborative trial using CRS-207 and Keytruda see ClinicalTrials.gov.

Originally posted here:

Companies Join Forces to Combat Mesothelioma - MesotheliomaHelp.org (blog)

Using Robotics for Mesothelioma Surgery – Asbestos.com (blog)

Robotics has changed the world of thoracic surgery for the better taking it to a whole new level.

It gives you the ability to do a more accurate, safer surgery, no matter what you are doing in the chest.

Minimally invasive robotics is performed with the da Vinci Surgical System. It involves two little hands, about eight millimeters long, controlled remotely by a surgeon at a computer board. It improves precision and maneuverability. A tiny camera provides a more magnified, three-dimensional view.

We do it well at Florida Hospital Celebration Health, which is home to the Global Robotics Institute, and we probably do more of these procedures than anyone in the world today.

Robotics is a fascinating topic when it comes to pleural mesothelioma. We recently had a mesothelioma patient come from England, where they arent doing major surgery for mesothelioma anymore. With the help of robotics here, he is back home today and doing well.

Robotics can play a few different roles with mesothelioma:

The robot in this scenario is a surgical tool rather than a platform, and its role is evolving still. This is not like taking out a prostate. You arent going to use the robot to resect a lung, and its not designed for that. It will, however, decrease the risk of complications.

Those three areas have been a problem with extrapleural pneumonectomy, an aggressive surgery for mesothelioma, and the robot can help immensely in all three of those areas.

One of the reasons major surgery has failed overall for mesothelioma is the inability to identify and pick the right candidates for surgery. The robot is really opening a new vista into understanding who should have this surgery, and who should not. Too many times, it has been done on the wrong patients.

The problem is that until you get into the chest, youre not totally sure what you will find, even after all the scans and other tests youve done. Too many times a surgeon will open the chest, and then realize this was not a good surgical candidate.

After a multidisciplinary workup and after youve determined the patient is a reasonable candidate for surgery, the robot comes into play in the operating room. Heres how:

By using the robot, you really reduce blood loss, and the complications that come with so much blood loss, which is one of the biggest problems typically. It leads to increased mortality and morbidity.

With the robot, you lose about one-tenth of the blood. Its a night-and-day difference when it comes to recovery.

At any point, if you see something you dont like, and you determine this is not a good candidate, you pull out and no real damage is done.

Without the robot and the camera, a surgeon may open the chest and realize this was not a good candidate. But its too late. Youve burned your bridges. There is no stopping then.

A surgeon will move forward with this huge operation that the patient may not survive, or the surgery does nothing but hurt the patients quality of life.

The robot can prevent these mistakes from happening. And they happen all the time without a robot.

If youre in there with the robot and you see the disease already has gone across the pleura and into the chest wall, that patient should not be having surgery. You stop.

Thats not something you should find after youve gone into the chest with traditional surgery. By then, its too late.

Its all about timing with the robot.

So now you know its resectable; the blood loss is under control; and youve taken the tumor cells out of the tough to reach spaces.

You take the robot out and open the chest by connecting those three small incisions, and its a straight-forward operation taking out the lung, pericardium and anything else you need. Its a relatively easy surgery to do.

With robotics, it is absolutely critical for a patient to go to a center doing a high volume of robotic surgeries like we do at Celebration Health. Robotics cant be done properly by a center that is just dabbling in it. You want experience, and lots of it.

Mesothelioma is such a horrible disease. The only role I see for aggressive surgery is for a patient who can go all the way. If the patient cant go all the way, then dont go at all. Thats important. Otherwise, you are doing more harm than good.

The key point in all this is knowing exactly who will benefit from surgery, and who will not. You need the robot for that.

The nonsurgical therapy that is out there, chemotherapy and radiation, just doesnt work really well. Robotics is about tweaking the surgery to help some of these patients do well.

When I worked at the University of Arizona Health Network, we did the worlds first robotic surgery for mesothelioma in January 2013. That patient is still alive and doing well today.

It makes me feel there is something to all this.

Dr. Farid Gharagozloo is the medical director of cardiothoracic surgery at Florida Hospital Celebration Health. While at the University of Arizona in 2013, he became the first surgeon in the world to successfully use robotics to perform an extrapleural pneumonectomy (EPP), the most aggressive treatment available for mesothelioma. Others now have followed his lead.

See the original post:

Using Robotics for Mesothelioma Surgery - Asbestos.com (blog)

Symptoms of Mesothelioma – Critical Signs to Watch For

Patients in the early stages of pleural mesothelioma do not exhibit many symptoms. Those that do show are not specific to the disease. Mesothelioma symptoms common in the early stages are:

These are similar to symptoms of various other disorders, such as pneumonia, common cold, asthma, influenza, and Chronic Obstructive Pulmonary Disease (COPD). Pleural effusions and inflammation in the lining of the lungs are the main source of discomfort associated with mesothelioma, but are also linked to pneumonia and COPD.

Up to 25 percent of patients have symptoms like dyspnea and chest pain for approximately 6 months before seeing a doctor.

Pleural thickening is another result of pleural mesothelioma that is common in other diseases. This is caused by the scarring of the pleura. It causes a loss of elasticity in the lungs, which is essential for the lung to expand for normal breathing.

Pleural thickening can also be caused by tuberculosis, pleurisy, and empyema (infection in the lung that causes a buildup of pus in the pleura). However, in mesothelioma, this is specifically caused by scarring of the pleura due to asbestos.

Read the original post:

Symptoms of Mesothelioma - Critical Signs to Watch For

Mesothelioma Victims Center Now Urges a Coal Miner with … – PR Newswire (press release)

NEW YORK, June 26, 2017 /PRNewswire/ -- The Mesothelioma Victims Center says, "Some of our own family grew up in the mining industry, so we are incredibly passionate about making certain any miner with mesothelioma receives the best possible compensation because of their exposure to asbestos. As we would like to discuss anytime at 800-714-0303, any miner with mesothelioma that does not have the best possible legal representation will probably not receive the very best financial compensation settlement." http://MesotheliomaVictimsCenter.Com

When a person with mesothelioma or their family hires a lawyer or law firm to assist with mesothelioma, they will typically work with that attorney or law firm until the compensation process ends. The major downside to this is that it becomes virtually impossible to fire an attorney part way through a compensation claim if the family becomes aware of how incompetent or inexperienced the attorneys may be.

It is for this reason the Mesothelioma Victims Center urges people with mesothelioma or their family to call them before hiring a lawyer or law form to assist with the mesothelioma financial compensationclaim.

According to the group, "We know most people want nothing to do with lawyers. As we would like to explain anytime at 800-714-0303, when it comes to mesothelioma compensation or getting the best financial settlements, you will need to have the nation's most skilled, experienced, and capable mesothelioma attorneys. Believe it or not, some of the nation's top mesothelioma attorneys will take a coal miner's mesothelioma compensation claim because they are just as passionate as we are about getting their clients the best financial settlement results."

Vital tip for any coal miner or their family from the Mesothelioma Victims Center: "If the lawyer you are talking to cannot produce family references where he/she was the driving force for a coal miner getting a substantial mesothelioma compensation settlement, please call us anytime at 800-714-0303 for direct access to some of the nation's top mesothelioma attorneys who have these kinds of references. Let us explain how to avoid being overcharged by lawyers working on a mesothelioma compensation claim. http://MesotheliomaVictimsCenter.Com

In 2015, roughly 897 million short tons of coal were produced in 25 states. Five states produced a total of about 639 million short tons, or about 71% of total U.S. coal production. The five largest coal producing states with production in million short tons and the share of total U.S. coal production in 2015:

For more information please visit the US Energy Information Energy Administration's website on this topic: https://www.eia.gov/tools/faqs/faq.php?id=69&t=2.

Each year about 3000 US citizens will be diagnosed with mesothelioma. Mesothelioma is caused by exposure to asbestos. High -risk work groups for exposure to asbestos include US Navy Veterans,power plant workers, shipyard workers, oil refinery workers, steel mill workers, miners,manufacturing workers, pulp or paper mill workers, millwrights, welders, plumbers, electricians, auto mechanics, machinists, construction workers, rail road workers, and firemen. Typically, the exposure to asbestos for these types of workers occurred in the 1950's, 1960's, 1970's, or 1980's.

According to the CDC the states indicated with the highest incidence of mesotheliomainclude Maine, Massachusetts, Connecticut, Maryland,New Jersey, Pennsylvania, Ohio, West Virginia, Virginia,Michigan, Illinois, Minnesota, Louisiana, Washington, and Oregon.

The Mesothelioma Victims Center says, "As we would like to explain anytime at 800-714-0303 if a person who has been diagnosed with mesothelioma wants the best possible compensation it is vital they have the nation's most skilled, and experienced mesothelioma lawyers." http://MesotheliomaVictimsCenter.Com

For more information about mesothelioma please refer to the National Institutes of Health's web site related to this rare form of cancer: http://www.nlm.nih.gov/medlineplus/mesothelioma.html

Contact: Michael Thomas 800-714-0303 163192@email4pr.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mesothelioma-victims-center-now-urges-a-coal-miner-with-mesothelioma-or-their-family-to-call-for-on-the-spot-access-to-some-of-the-nations-top-lawyers-for-compensation-results-300479008.html

SOURCE Mesothelioma Victims Center

Mesothelioma Victims Center

Here is the original post:

Mesothelioma Victims Center Now Urges a Coal Miner with ... - PR Newswire (press release)

Scientists "Turn Off" Tumor-Protecting Protein in New Mesothelioma Study, According to Surviving Mesothelioma – Benzinga

New research suggests that microRNAs may be the key to downregulating PD-L1 and improving immunotherapy treatment for malignant mesothelioma.

Raleigh, NC (PRWEB) June 25, 2017

Australian researchers studying the protein PD-L1 have developed a way to potentially turn off the mechanism that lets mesothelioma tumors hide from the immune system. Surviving Mesothelioma has the full story. Click here to read it now.

Doctors at the Asbestos DIseases Research Institute at the University of Sydney found key differences in the action of certain microRNAs among mesothelioma patients with elevated levels of PD-L1.

"In the same patient series, PD-L1 expression was also associated with downregulation of microRNAs previously shown to have tumour suppressor activity in malignant pleural mesothelioma," writes Steven C. Kao, the lead author on the paper.

According to the study in the Journal of Thoracic Oncology, the researchers determined that it is possible to downregulate PD-L1 expression by inserting "mimic" microRNAs into mesothelioma cells in the lab.

"This is especially noteworthy since mesothelioma patients who test positive for PD-L1 overexpression are more likely to have a non-epithelioid type of mesothelioma and poorer odds of survival," says Alex Strauss, Managing Editor for Surviving Mesothelioma.

For the details of the new clinical trial and more about PD-L1 and microRNAs in mesothelioma, see MicroRNAs May Be Key to Better Immunotherapy for Mesothelioma, now available on the Surviving Mesothelioma website.

Kao, SC, et al, "Tumour suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma", June 16, 2017, Journal of Thoracic Oncology, Epub ahead of print, http://www.jto.org/article/S1556-0864(17)30460-4/fulltext

For more than a decade, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

For the original version on PRWeb visit: http://www.prweb.com/releases/2017/06/prweb14458786.htm

Continue reading here:

Scientists "Turn Off" Tumor-Protecting Protein in New Mesothelioma Study, According to Surviving Mesothelioma - Benzinga

Mesothelioma Survival Rate | Factors Affecting Survivorship

Approximately 55 percent of mesothelioma patients live longer than 6 months, while roughly 35 percent live longer than one year. Only 9 percent of people diagnosed with mesothelioma survive longer than 5 years.

This question is commonly asked by those who have been diagnosed with mesothelioma, a fatal form of cancer caused by asbestos. Unfortunately, as with most diseases, there is no one answer to how long a mesothelioma patient will live.

The good news is that survival rates for mesothelioma patients are improving. A 2015 meta-study looked at 20 years worth of results from 1992 2012, and during that period the two major forms of mesothelioma (pleural and peritoneal) have both seen an improvement in survivorship.

According to the study, peritoneal mesothelioma survivorship has especially shown significant improvement, largely due to new forms of treatment, such as hyperthermic intraperitoneal chemotherapy (HIPEC).

The type of treatment a mesothelioma patient receives can affect survival rates. Whether this is due to the treatment itself or to other factors (e.g., if the patient is too ill to undergo a more aggressive treatment) may not always be apparent. While there has been no single study showing survival rates based on treatment across all types of mesothelioma, separate studies have been done on the two most common forms of mesothelioma.

For pleural mesothelioma, patients who undergo a pleurectomy/decortication (P/D) or extrapleural pneumonectomy (EPP) both of which are usually part of a multimodal treatment plan generally have a much higher rate of survival than those who receive chemotherapy alone.

For peritoneal mesothelioma, patients who undergo cytoreductive surgery (CRS) with HIPEC have significantly higher rates of survival. When combined with systemic chemotherapy as an adjuvant treatment, the 5-year survival rate of patients who undergo CRS + HIPEC can be as high as 67%.

The survival rate for mesothelioma patients depend on a variety of factors. These include things such as the patients age, health, and the treatment they receive. Ever individual case is different, and one survival rate may not necessarily apply to a specific patients case.

Mesothelioma staging can impact survival rate significantly. Patients diagnosed at an early stage (Stage I or Stage II) have a much higher survival rate than those diagnosed at a later stage (Stage III or Stage IV). For example, the 5-year survival rate for Stage 1 peritoneal mesothelioma patients is 87 percent, but only 29 percent for Stage IV.

Younger mesothelioma patients have higher rates of survival than older patients. This is due in part to the fact that older people in general have lower survival rates. In addition, with age comes a variety of health-related conditions that can make a mesothelioma diagnosis more deadly.

According to data provided by the National Cancer Institutes SEER database, women have a higher 5-year survival rate (16%) than men (9.3%). It is not entirely clear why this is so, though some reasons may include that women are generally diagnosed at a younger age, they are more likely to get regular medical checkups, and they may be in better overall health.

There is some evidence that African-Americans who have mesothelioma have a slightly longer 5-year survival rate than Caucasian mesothelioma patients. However, because Caucasians have a much higher incidence of mesothelioma, there may not be enough cases of African-Americans who have the disease to make a substantive determination.

Several studies have shown that certain genetic factors can affect survival rates among patients. For example, mesothelioma patients who have certain mutations of BRCA1-associated protein-1 (BAP1) appear to have much better survival rates than other individuals who develop the disease, according to one study.

Mesothelioma survival rates are determined by a standard measure known as the relative 5-year survival rate, which indicates how many patients are still alive 5 years after being diagnosed with the disease.

According to the most reliable studies, the relative 5-year survival rate for mesothelioma is about 9 percent, which is better than it was a decade or more ago. However, this simplified number does not tell the whole story. As shown above, survival rate can depend heavily on the type of mesothelioma a person has, what treatment options are available to them, and certain other health and lifestyle factors.

Many different clinical trials and other studies are being conducted on an ongoing basis to identify the factors that affect survival rate and, hopefully, discover ways to increase survival among mesothelioma patients. The results of these studies can be helpful for patients who meet certain criteria, but they may not be useful for determining an overall survival rate across the broad spectrum of mesothelioma patients.

Therefore, while survival rate can be a useful statistic in some cases, it can be misleading in others. Patients and loved ones should always rely on the advice and guidance provided by their doctors to understand how they can improve their prognosis and life expectancy, rather than looking to a single statistic.

American Cancer Society. Learn About Cancer: Malignant Mesothelioma.

Baumann, Francine, et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Cancer Research. 2016; 76(2):206-215. DOI: 10.1093/carcin/bgu227

Faig, Jennifer, et al. Changing Pattern in Malignant Mesothelioma Survival. Translational Oncology. February 2015; 8(1):35-39. DOI: 10.1016/j.tranon.2014.12.002

Hassan, R. "Mesothelin Targeted Cancer Immunotherapy." European Journal of Cancer. August 2007. DOI: 10.1016/j.ejca.2007.08.028

Kepenekian, V., et al. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database : Multi-Institutional Retrospective Study. European Journal of Cancer. September 2016; 65:69-79. DOI: 10.1016/j.ejca.2016.06.002

Milano, Michael T., and Zhang, Hong. Malignant Pleural Mesothelioma: A Population-Based Study of Survival. Journal of Thoracic Oncology. November 2010; 5(11):1841-1848. DOI: 10.1097/JTO.0b013e3181f1cf2b

SEER Cancer Statistics Review 1975-2013. National Cancer Institute.

Oliveira, Guilherma H., et al. Characteristics and Survival of Malignant Cardiac Tumors: A 40-Year Analysis of Over 500 Patients. Circulation. 14 October 2015; DOI: 10.1161/CIRCULATIONAHA.115.016418

Sciarrillo, Rocco, et al. Abstract 332: Spliceosome inhibition as novel strategy against diffuse malignant peritoneal mesothelioma. Cancer Research. 15 July 2016; 76(14 Suppl):Abstract nr 332. DOI: 10.1158/1538-7445.AM2016-332

View original post here:

Mesothelioma Survival Rate | Factors Affecting Survivorship

MicroRNAs May Be Key to Better Immunotherapy for Mesothelioma – Surviving Mesothelioma

Australian scientists say it may be possible to artificially reduce the levels of a protein that helps mesothelioma tumors hide from the immune system.

The new research published in the Journal of Thoracic Oncology could open the door to more effective immunotherapy treatments for pleural mesothelioma.

A cell surface protein called PD-L1 is key to the effectiveness of several new immunotherapy drugs including Keytruda (pembrolizumab), Opdivo (nivolumab), and avelumab.

An estimated 40 percent of mesothelioma tumors overexpress this protein, which is part of the processthat allows several different kinds of cancers to escape detection and attack by the immune system.

Now, a new study conducted at the Asbestos Diseases Research Institute at the University of Sydney has revealed more about the mechanismsbehind PD-L1 expression in malignant mesothelioma. The results suggest that it may be possible to downregulate this tumor-protecting protein from the inside out.

MicroRNAs are short, single-stranded RNA molecules that regulate gene expression,which, in turn, governs all kinds of cellular processes.

Among 72 test subjects with malignant pleural mesothelioma, the Australian team found that 18 (25%) tested positive for PD-L1 overexpression. The PD-L1-positive mesothelioma patients showed key differences in the action of certain microRNAs.

In the same patient series, PD-L1 expression was also associated with downregulation of microRNAs previously shown to have tumour suppressor activity in malignant pleural mesothelioma, writes Steven C. Kao, the lead author on the paper.

When the researchers manipulated these microRNAs by transfecting mesothelioma cell lines with artificial microRNAs or mimics, they found that they were able to downregulate the expression of the PD-L1 protein.

The new findings are significant because mesothelioma patients who overexpress PD-L1 have poorer outcomes than patients who dont.

The Australian researchers found that test subjects whose mesothelioma tumors tested positive for PD-L1 were more likely to have either the biphasic or sarcomatoid subtype of mesothelioma and tended to experience shorter survival.

The median overall survival of the PD-L1-expressing mesothelioma patients was just 4 months, compared to 9.2 months for the mesothelioma patients with negative PD-L1 staining.

Together, these data suggest that tumour suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma, writes Dr. Kao.

Source:

Kao, SC, et al, Tumour suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma, June 16, 2017, Journal of Thoracic Oncology, Epub ahead of print

Continue reading here:

MicroRNAs May Be Key to Better Immunotherapy for Mesothelioma - Surviving Mesothelioma

Mesothelioma Law Firm | Sokolove Law

Trusted Nationwide for Mesothelioma Legal Services

The national reach of Sokolove Law allows us to help victims in any state, and to maximize the value of their cases and potential settlements.

Our goal is to maximize the compensation that a mesothelioma victim may be entitled to. What makes Sokolove Law unique is that we are not restricted to filing lawsuits in certain states. As a national law firm, we will file wherever a mesothelioma or asbestos-related claim can be best litigated, in order to increase the value of a case.

For more information, we recommend reading: 5 Tips for Finding the Right Mesothelioma Lawyer for You

A mesothelioma law firm, or a law firm that specializes inasbestos cases, files claims on behalf of those suffering from diseases triggered by asbestos, which includes mesothelioma. These firms develop a deep understanding of the nitty-gritty details involved in bringing justice to the victims and families impacted by these devastating diseases.

Torts, as theyre known, or, more commonly, civil actions, are part of an extremely complex area of the law. This is the area where asbestos litigation falls. All U.S. states have their own unique statutes, and these statues can vary on things like burden-of-proof, meaning one states requirements could be different or even more demanding than anothers.

Thats why its best to work with an experienced lawyer. Firms like Sokolove Law have for years prioritized keeping up with the latest mesothelioma research and asbestos-related legal developments. Sokolove Law maintains massive databases containing information related to virtually every aspect of the asbestos industry.

Whenever youre considering legal action, its vital that you interview a potential law firm and check their past experience in mesothelioma claims, settlements and specialized legal experience.

Here are some questions you might ask if you were looking to partner with a mesothelioma law firm:

How many years of experience does yourmesothelioma law firm have?

Will youtake mycase on a contingency basis?

What are the typical outcomes of yourmesothelioma cases? Out-of-court settlement? Win? Loss? Appeal?

Will Ibe able to speak with members of yourlaw firm as needed? Will mycalls be returned promptly and your questions answered clearly?

How many mesothelioma (not just asbestos) cases or claims has yourlaw firm handled?

Will mycase be handled on an individual basis, or bundled with several other similar cases? (This may hurt you if your case is a strong one, but could be helpful with weaker cases.)

Does your mesotheliomalaw firm have a nationwide network of attorneys and lawyers who will share their research and expertise in order to build a solid case on mybehalf?

Will yourlaw firm be handling mycase personally? (At times law firms may refer your case to another firm that may be better suited to help in your situation often providing you with the services of both their firm and another at no extra cost to you.)

Remember, its in your best interest to be comfortable with the mesothelioma law firm and attorneys that handle your case.

Sokolove Laws staff of experienced mesothelioma paralegals is here to help you and to answer any questions you might have about filing a mesothelioma lawsuit. Dont wait request a free legal consultation today.

Read the original post:

Mesothelioma Law Firm | Sokolove Law

Mesothelioma Veterans Center – Access Benefits & VA Claims

Choose Your Service Branch Below What is Mesothelioma?

Mesothelioma is a cancer of the lining of the lungs (pleural mesothelioma) or abdomen (peritoneal mesothelioma) that is caused by exposure to asbestos. In over 30% of all mesothelioma cases, asbestos exposure happened during military service. Veterans from all branches of service are at risk, with the most common being the United States Navy and the Marines. There are a variety of mesothelioma treatments available, as well as doctors in the VA system who are capable of treating it.

Veterans Benefits are available for people in the form of VA Disability, Aid & Attendance and more. Learn more about Asbestos in the military and the benefits available for you.

Learn more about this disease that affects the lining of the lungs (pleural) or abdomen (peritoneal). Find the top treatment options and ways to improve your prognosis.

Veterans with mesothelioma are often eligible for thousands of dollars in disability compensation, access to top mesothelioma specialists and more.

Hundreds of thousands of veterans were exposed to asbestos during their service in the military. Learn how and where you may have been exposed.

[data-image-id='gourmet_bg']

[data-image-id='gourmet_bg']

[data-image-id='gourmet_bg']

[data-image-id='gourmet_bg']

[data-image-id='gourmet_bg']

[data-image-id='gourmet_bg']

[data-image-id='gourmet']

[data-image-id='gourmet']

[data-image-id='gourmet']

[data-image-id='gourmet']

[data-image-id='gourmet']

[data-image-id='gourmet']

[data-image-id='gourmet']

[data-image-id='gourmet']

[data-image-id='gourmet']

[data-image-id='gourmet']

Read the original post:

Mesothelioma Veterans Center - Access Benefits & VA Claims

Malignant Mesothelioma (Asbestos Cancer) > The Mesothelioma …

Malignant mesothelioma (pronounced "mez-o-theel-e-oh-ma"), also known as "asbestos cancer," is a rare form of cancer found in the lining of the heart, lungs, abdomen, or the internal reproductive organs. This lining is called the mesothelium and is where mesothelioma gets its name.

Because tumors of the mesothelium are rarely benign (non cancerous), cancerous malignant mesothelioma is usually referred to simply as "mesothelioma," or in casual terms simply "meso."

The mesothelium covers various organs in the body protecting them and allowing organs to move against each other as the lungs expand and contract or the heart beats. Where the mesothelium covers the internal organs, it is called the visceral mesothelium and where it covers the body walls, it is called the parietal mesothelium.

Malignant mesothelioma occurs when cells within the mesothelium become abnormal and divide uncontrollably. If not caught early enough, the cancer may metastasize, spreading to other organs of the body. While it is a very aggressive form of cancer, several treatment options are available for malignant mesothelioma.

The only known cause of mesothelioma is asbestos. Because asbestos exposure is the only known cause of mesothelioma, it is sometimes referred to as "asbestos cancer." However, malignant mesothelioma is not the only cancer caused by asbestos. Exposure to asbestos can also cause laryngeal, colon, and lung cancer.

There is no known safe level of asbestos exposure, but asbestos cancers are dose dependent, meaning those exposed for longer periods of time and to greater amounts of asbestos are more likely to develop asbestos-related disease. If you were exposed to asbestos, you should tell your physician so he or she can make a determination for appropriate testing based on your history of exposure and symptoms.

One of the earliest descriptions of malignant mesothelioma was written in 18701, although the tumor was referred to as tuberkelhnliche lymphadenome ("tubercle-like" lymphadenoma) in this early, German-language review. It wasn't until the start of the 19th century that tumors arising out of the mesothelium were named mesotheliomas. The process of appropriately identifying, and thus naming, mesothelioma was not without some debate, confusion, and even controversy.

In an article that would help define the modern ideas on the pathology and diagnosis of mesothelioma, Klemperer and Rabin's 1930 "Primary Neoplasms of the Pleura: A Report of Five Cases" noted that thirty different names had been used to describe the neoplasms being studied:

The names applied most frequently, endothelioma, endothelial carcinoma, carcinoma, sarcoma, lymphangitis proliferans, sarcocarcinoma and mesothelioma, are indicative of the different morphologic pictures and the different opinions of the authors as to the point of origin. To make this confusion more complete, there have been included in the literature on primary tumors of the pleura a number of cases that, on critical examination, are proved to originate definitely in the lungs or in the bronchi."2

Even as late as 1943the year many consider asbestos was determined a cause mesothelioma (see Wedler, below)researchers suggested "pleuroma" as a name for these tumors3, however, mesothelioma gradually became the accepted term. Likely as a result of relative rarity of mesothelioma, the connections between asbestos and mesothelioma began to be made even as mesothelioma itself was still not well understood or identified.

In 1933, London pathologist Steven Roodhouse Gloyne published a study in which he discussed the movement of asbestos fibers through the lymph system and the particularly high concentrations of asbestos that collected in the lymph nodes in the central chest in a person with asbestosis4. Two years later, in 1935, Gloyne is considered the first to make a possible connection between occupational asbestos exposures and mesothelioma.

Gloyne described malignancies arising from the pleura of an asbestosis victim5, noting that "at the moment" there was no indication that the tumor correlated to the asbestosis present. However, in 1938, when the German government began to recognize and compensate lung cancer as an occupational disease of asbestos workers, mesothelioma was included as a compensable respiratory cancer.

What is often regarded as the first study to connect mesothelioma with asbestos was published in 1943 by German researcher, Dr. H.W. Wedler6. Wedler reviewed a collection of autopsy records belonging to asbestosis victims, his results revealing an excess of both lung and pleural malignancies. Also of interest in Wedler's study, was his observation of an often a long interval between exposure and the development of cancer and his assertion that these diseases must be regarded as occupational.

Several more publications in a similar vein followed, and throughout the 1940s and 1950s, articles discussing asbestosis cases often mentioned accompanying lung cancers and/or mesotheliomas. In 1954, F. Leicher reported the first case of peritoneal mesothelioma in an asbestos textile factory spinner7. Many researchers, physicians, and other specialists believe the causal relationship between asbestos and mesothelioma was, or at least could, have been established by the mid-1950s. (Interestingly, even as late as 1955, some studies did not refer directly to "mesothelioma," but to a malignancy of the pleura or similar.)

It was an article published by South African researchers J.C. Wagner, Christopher Sleggs, and Paul Marchand that is generally attributed as the removing any doubts that asbestos causes mesothelioma. Wagner had initially been hired by the South African Government Mining Engineer to study occupational diseases, namely, asbestosis; however, Wagner began to focus his attention on the unusual pleural tumors he was finding during his research. It was not a decision the mining industry in South Africa was happy about, as they were busy investing in new operations to meet the growing global demands for asbestos.

The study, first presented at a conference in Johannesburg in 1959 and published in 1960 in the British Journal of Medicine, detailed 33 cases of mesothelioma with all but one case having a proven asbestos exposure history. In eight cases, their exposure history was occupational, however, some twenty of the mesothelioma cases discussed simply lived as infants near the mines.

Although the language of Wagner's study left the association between asbestos and mesothelioma "possible," the results of such damaging evidence against asbestos in occupational and, perhaps more importantly, bystander asbestos exposures was not lost on the industry. Partly as a result of pressures from industrial interests, Wagner left South Africa in 1962 for a new position in the UK. Any lingering doubts about asbestos' tie to mesothelioma left open by Wagner were shortly quieted by several studies which further confirmed the link.

In the 50s and 60s, New Jersey physician Irving J. Selikoff saw several men suffering from pulmonary abnormalities as a result of inhaling asbestos dust on the job at the Patterson, NJ UNARCO (Union Asbestos & Rubber Company) plant. UNARCO's specialty was in producing asbestos insulation materials for the US Navy. When several of Selikoff's UNARCO patients died as a result of cancer, he contacted UNARCO requesting their participation in a study of workers' health.

When UNARCO declined, Selikoff tried a different tactic. If the makers of the insulation were being injured by asbestos, Selikoff supposed, those installing it might face similar risks. Early in 1962, Selikoff contacted the International Association of Heat & Frost Insulators & Asbestos Workers (New York Local 12 and Newark Local 32). The union officials were, in fact, quite concerned about workers' health. So much so, that they had contacted the Industrial Hygiene Foundation (IHF) about them several years prior. Originally called the Air Hygiene Foundation, the IHF was almost wholey industry-funded, so their responses to the union's concerns were, not surprisingly, reassurances about the safe handling of asbestos insulation materials.

Over the course of the next year, Selikoff examined more than a thousand insulators, performing pulmonary function tests and administering x-rays. Selikoff finally presented his findings in 1964 at the New York Academy of Science sponsored conference 'Biological Effects of Asbestos.' His results were staggering. Among the insulators, mortality was 25% higher than was expected, and not from asbestosis alone, but from lung cancer, stomach cancer, colon cancer, rectal cancer, colorectal cancer, and malignant mesothelioma.

Along with Selikoff's presentation at the 1964 conference, Wagner and other researchers presented further evidence of the connection between asbestos and mesothelioma. British physician Molly Newhouse echoed Wagner's own findings when she presented her research regarding mesothelioma cases among people who lived near, but were not employed by, a London asbestos factory. Many of the presentations emphasized that victims often did not suffer long or heavy exposures, work with asbestos, nor have asbestosis.

In 1968, the British Medical Journal asserted that "at the end of 1965, it was clear that asbestos workers [were] at special risk of developing cancers of at least two typebronchial carcinoma and mesothelioma."

Last update: December 03, 2015. 02:54:51 pm.

Original post:

Malignant Mesothelioma (Asbestos Cancer) > The Mesothelioma ...

Time Between Surgeries Helps Predict Mesothelioma Survival – Asbestos.com

A new study from researchers at the City of Hope cancer center in Los Angeles and Wake Forest University School of Medicine in Winston-Salem, North Carolina, reveals how the length of time between initial and follow-up cytoreduction surgery and HIPEC plays a role in patient survival.

The study, published in June in the Journal of Surgical Oncology, shows peritoneal mesothelioma patients who repeat the procedure between one and two years after the initial surgery have the most favorable outcome, with a median overall survival of nearly four years.

Peritoneal mesothelioma is an aggressive, asbestos-related cancer, and recurrence is common.

These results are very promising for a select group of patients who recur after cytoredutive surgery (CRS) and HIPEC, Dr. Konstantinos Votanopoulos, associate professor of surgery at Wake Forest School of Medicine, told Asbestos.com. In this group, a complete CRS and HIPEC essentially resets the clock in terms of anticipated survival.

The multimodal approach of CRS followed by heated intraperitoneal chemotherapy (HIPEC) is the standard treatment option for peritoneal mesothelioma patients.

In 2013, researchers at Moffitt Cancer Center concluded patients who opted for a second procedure survived nearly three times as long as those who underwent only one procedure.

The goal of CRS, also known as debulking, is to remove any visible tumors or cancer from multiple sites in the abdomen. It may require removing some or all parts of major organs, including the gallbladder, liver, pancreas, stomach, spleen and intestinal tract.

HIPEC involves delivering heated chemotherapy drugs directly to the abdominal cavity to treat any cancer cells that may remain. It is considered a risky procedure, and not all peritoneal mesothelioma patients are candidates.

Sometimes, multiple rounds of HIPEC are necessary to send the cancer into remission.

In addition to peritoneal mesothelioma, CRS and HIPEC are used to treat other gastrointestinal cancers and peritoneal surface malignancies including cancers of the colon, appendix and gallbladder.

Using a City of Hope database of 1,314 CRS and HIPEC procedures performed between February 1993 and December 2015, Konstantinidis and his team identified 103 (8.5 percent) patients who underwent repeat procedures.

The group included:

Mesothelioma patients carried the most significant disparity of overall survival, according to the time interval between first and second CRS and HIPEC procedures.

Overall survival rates for peritoneal mesothelioma patients in the study were:

Median overall survival for all peritoneal mesothelioma patients in the study was 2.4 years.

All other cancer patients who underwent repeat procedures after two years saw a significant increase in overall survival compared to those in the one- to two-year range, including a four-year difference for low-grade appendiceal cancer and three-year difference for colon cancer patients.

The median overall survival for all cancers in that interval was seven years, far longer than mesothelioma patients in that group, for all patients who underwent repeat procedures after at least two years. This can be attributed to the high recurrence rate of peritoneal mesothelioma and its ability to spread quickly.

Although the study links repeated procedures more than two years after initial surgery with the best overall survival, the optimal time interval for mesothelioma patients is between the first and second year.

Essentially, the amount of time between procedures functions as a powerful selection tool to predict the patients that will do well, Votanopoulos said. A recurrence within a year from the initial operation is a sign that the tumor is very aggressive and more surgery is unlikely to offer a survival benefit.

Researchers at Wake Forest were part of a 2015 study analyzing the survival-time gap between the two most common types of mesothelioma peritoneal and pleural.

The study showed the median survival for peritoneal patients is four times that of a patient diagnosed with pleural mesothelioma, which develops on the protective lining surrounding the lungs and accounts for roughly 70 percent of all mesothelioma cases.

Median survival for peritoneal patients was more than six years, compared to just 18 months for pleural patients.

Advancements in therapy, most notably the cytoreductive surgery and HIPEC procedures, are credited for the significant difference in prognosis between the two types.

Combining heated chemotherapy with aggressive surgery has not been as successful for treating pleural mesothelioma.

There are still limitations for CRS and HIPEC. Peritoneal patients are eligible on a case-by-case basis, depending on tumor growth and whether the cancer has spread outside of the abdominal cavity.

But ongoing research continues to demonstrate the procedures as the standard therapy for peritoneal mesothelioma.

A complete CRS and HIPEC, or in other words resection of all visible tumor, is the most important factor in predicting improved survival, Votanopoulos said. Therefore, early detection of recurrence when the volume of disease is low is of paramount importance.

Read more:

Time Between Surgeries Helps Predict Mesothelioma Survival - Asbestos.com

Testicular and Cardiac Mesothelioma – Surviving Mesothelioma

Most cases of mesothelioma occur around the lungs (pleural) or around the abdomen (peritoneal). However, there are two rare subtypes that can occur. One is found around the testis and the other can be found around the heart. Estimates place each type to less than 50 cases a year.

Testicular Mesothelioma is also called paratesticular or mesothelioma of the tunica vaginalis testis. It is a rare subtype of mesothelioma that involves the testis.

A major risk factor is exposure to asbestos, typically with a long latency between exposure and diagnosis.

The most common symptom is a mass or hydrocele (buildup of fluid) inside the scrotum. Symptoms of testicular mesothelioma may include scrotal problems, pain, and discomfort. Your doctor may use a physical examination, X-ray or other imaging to detect the lesions. An ultrasound may also be used. A biopsy may be performed and the tumor may be examined by a pathologist to determine exactly what type of cancer it is. Pathologists use immunohistochemical staining to help them identify the genetic markers of various cancers.

Treatment of testicular mesothelioma may include surgery followed by radiation therapy and chemotherapy. Recent studies have concluded that surgery may be curative in some cases. For example, in one study, two patients with this disease were treated by radical inguinal orchiectomy where one or both testicles and the spermatic cord are surgically removed. According to their doctors, Both patients are currently in complete remission. These doctors go on to say that the use of chemotherapy and radiation therapy may not always be necessary in this type of mesothelioma. However, other studies have concluded that treatment is only curative in early stages.

The mortality rate from testicular mesothelioma has been reported to be 53% over a mean follow-up time of two years. Even with treatment, this tumor has a very poor prognosis with a median survival of about 23 months.

Pericardial Mesothelioma an extremely rare subtype of the asbestos-caused cancers. The cancer develops within the pericardium, the membrane that surrounds the heart. This membrane actually has two layers: An outer layer called parietal and an inner layer known as visceral.

Primary pericardial malignant mesothelioma is extremely rare with an incidence less than 0.0022%. It comprises 0.7% of all mesothelioma cases. As of 2012, approximately 350 cases of pericardial mesothelioma have been reported in the peer reviewed medical literature.

Due to its rarity and lack of studies, the role of asbestos in pericardial mesothelioma is unclear.

The symptoms of pericardial malignant are usually not specific and may resemble those of other heart conditions. The symptoms may also relate to a fluid buildup around the heart and thickening of the pericardial layers. The symptoms may also be related to constrictive pericarditis, heart attack, or congestive heart failure. Symptoms that have been reported include: heart palpitations or irregular heartbeat (arrhythmia), difficulty breathing, shortness of breath, fatigue and chest pains. If you are experiencing any of these symptoms see your licensed healthcare provider immediately.

Treatment options are limited because the tumors are so close to the heart.

With the exception of a handful of case reports, patients typically pass away within 6-10 months of diagnosis. An example of a longer term survivor is a 59-year-old woman who underwent surgery for malignant pericardial mesothelioma. The tumor was successfully removed with clean surgical margins. The cell type of her mesothelioma was epithelioid. The patient tolerated the operation and chemotherapy without any complications. She remained alive for almost 3 years after surgery.

Read the original:

Testicular and Cardiac Mesothelioma - Surviving Mesothelioma

Targeted Therapy May Soon be Primary Approach for Mesothelioma Treatment – MesotheliomaHelp.org (blog)

Targeted care optimizes the potential for success of mesothelioma treatment and provides the patient with the assurance that his cancer is being treated according to his unique characteristics. Personalized cancer treatment is gaining popularity among physicians and oncologists, however, it is far from mainstream. If researchers from University of Michigan have their way, however, treatment for all cancers will soon be personalized based on the patients biomarkers.

In a new study released from researchers at the University of Michigan Comprehensive Cancer Center, the team looked at the DNA sequencing of nearly 500 patients. Of those, almost 75 percent of them had biomarkers that can be targeted by either existing or experimental anti-cancer treatments.

Biomarkers, including EGFR and PD-L1, that are present in mesothelioma and other cancers, help indicate the reason for the growth of the cancers and are the focus of current and experimental treatments used to fight the deadly disease. Many clinical trials are being offered now for mesothelioma patients that pinpoint particular biomarkers. One well-known trial is the Keynote-28 trial, that eight-year mesothelioma survivor Mavis Nye of England participated in, that targeted the PD-L1 marker and put her mesothelioma in remission.

Availability of biomarker trials is crucial for being able to act on these results, says Erin Cobain, M.D., clinical lecturer of hematology/oncology at the University of Michigan Medical School.

The value of the study lies in the method used to sequence the genes and the process for developing patient care based on the results of the sequencing. Using next generation sequencing the team reports that the genetic sequencing looks at all of the DNA and RNA expressed within a tumor, as well as sequencing the patients normal genome to identify genes that may be inherited from the patients parents.

Erin Cobain, M.D., University of Michigan

Using MI-ONCOSEQ, the tool developed at the Michigan Oncology Sequencing Center, the test uses a fresh biopsy from the patient, as opposed to frozen tissue samples used by commercially-available tools, allowing the Michigan researchers to perform a more comprehensive analysis. According to the press release, commercial tests analyze only about 350 genes compared to MI-ONCOSEQs ability to cover at least 1,700 genes.

Mesothelioma is an incurable, asbestos-caused cancer of the membranes that surround many of the bodys vital organs, including the lungs. The cancer is highly aggressive and is resistant to many cancer treatments making it a difficult disease to treat effectively. Thus, developing a treatment protocol that specifically targets the genetic makeup of the patients cancer is vital for improving survival rates.

More here:

Targeted Therapy May Soon be Primary Approach for Mesothelioma Treatment - MesotheliomaHelp.org (blog)

The Mesothelioma Victims Center Now Urges a Diagnosed Navy … – PR Newswire (press release)

NEW YORK, June 22, 2017 /PRNewswire/ --The Mesothelioma Victims Center says, "We are certain most people have seen a cable TV commercial sponsored by a law firm offering a free book about mesothelioma. Typically, this is a law firm's marketing effort to identify people who have mesothelioma, and in our opinion the book is the bait.

"If you are a US Navy Veteran or person with mesothelioma, we offer a higher quality resource than a generic book about an extremely rare form of cancer caused by asbestos exposure as we would like to discuss anytime at 800-714-0303. As an example, we offer instant access to the nation's leading mesothelioma attorneys who can completely explain the mesothelioma financial compensation process.

"Once we have some basic information about the person, we will do our own on-the-spot research to make certain the diagnosed Navy Veteran or person has access to their region's top oncologists, who have experience treating mesothelioma. A Navy Veteran or person with mesothelioma will not get these types of resources in a free book about mesothelioma. The physicians we suggest are not associated with a VA hospital because these hospitals, in our opinion, provide an inferior service for Veterans with an aggressive cancer such as mesothelioma as we would like to explain anytime at 800-714-0303." http://MesotheliomaVictimsCenter.Com

Customized services offered by the Mesothelioma Victims Center to any US Navy Veteran that are vastly superior to a generic book about mesothelioma:

"Mesothelioma should not tear a family apart as we would like to discuss anytime at 800-714-0303. Mesothelioma can hopefully bring a family together," says the Mesothelioma Victims Center. http://MesotheliomaVictimsCenter.Com

According to the CDC the states indicated with the highest incidence of mesotheliomainclude Maine, Massachusetts, Connecticut, Maryland,New Jersey, Pennsylvania, Ohio, West Virginia, Virginia,Michigan, Illinois, Minnesota, Louisiana, Washington, and Oregon.

However, based on the calls the Mesothelioma Victims Center receives a US Navy Veteran with mesothelioma could live in any state including New York, Florida, California, Texas,Illinois, Ohio, Iowa,Indiana, Missouri, North Carolina,Kentucky, Tennessee, Georgia,Alabama, Oklahoma, Arkansas, Kansas, Nebraska, North Dakota, Colorado, New Mexico, Utah, Nevada,Arizona, Idaho, or Alaska.

High-risk work groups for exposure to asbestos include US Navy Veterans, power plant workers,shipyard workers, oil refinery workers, steel mill workers,manufacturing/factoryworkers, pulp or paper mill workers, plumbers, electricians, auto mechanics, machinists, miners, construction workers, insulators, rail road worker, roofers, or firemen. As a rule, these types of workers were exposed to asbestos in the 1950's, 1960's, 1970's, or 1980's. US Navy Veterans make up about one-third of all US Citizens who are diagnosed with mesothelioma each year. http://MesotheliomaVictimsCenter.Com

The Mesothelioma Victims Center says, "When it comes to obtaining the best mesothelioma settlement, the quality of the attorney matters, as we would like to explain anytime at 800-714-0303. Please don't shortchange yourself when it comes to mesothelioma financial compensation." http://MesotheliomaVictimsCenter.Com

For more information about mesothelioma please refer to the National Institutes of Health's web site related to this rare form of cancer: http://www.nlm.nih.gov/medlineplus/mesothelioma.html

Media Contact:Michael Thomas163186@email4pr.com 800-714-0303

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-mesothelioma-victims-center-now-urges-a-diagnosed-navy-veteran-to-call-them-about-nations-top-lawyers-for-honest-answers-about-compensation-rather-than-a-generic-book-300478125.html

SOURCE Mesothelioma Victims Center

http://MesotheliomaVictimsCenter.Com

Read the original post:

The Mesothelioma Victims Center Now Urges a Diagnosed Navy ... - PR Newswire (press release)